Open AccessCase of benralizumab‐induced exacerbations of chronic spontaneous urticaria
Author(s) -
Magen Eli,
Komarova Irina,
Magen Israel,
Phirtskhalava Sofia
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5930
Subject(s) - benralizumab , medicine , immunology , dermatology , intensive care medicine , asthma , mepolizumab , eosinophil
The role of IL‐5 in chronic spontaneous urticarial (CSU) is unclear. It may be that benralizumab is an important bidirectional modifier of CSU; that is, blocking IL‐5 may improve CSU in some patients, but it is possible that it may worsen CSU in others.